DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAIN AG - Chief Business Officer Ludger Roedder is leaving the executive board with immediate effect
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG
/ Key word(s): Personnel
B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAIN AG - Chief Business Officer Ludger Roedder is leaving the executive board with immediate effect
07.07.2020 / 08:30
The issuer is solely responsible for the content of this announcement.
Change in the Management Board of BRAIN AG
Chief Business Officer Ludger Roedder is leaving the executive board with immediate effect
Zwingenberg, Germany
07 July 2020
The biotechnology company B.R.A.I.N. Biotechnology Research and Information Network AG announces that Chief Business Officer Ludger Roedder will leave the executive board by mutual agreement with immediate effect on July 7th, 2020 due to different strategic visions. Mr. Roedder will leave the BRAIN AG at the end of the calendar year.
Dr Georg Kellinghusen, Chairman of the Supervisory Board, states: "We like to thank Ludger Roedder for his contribution and commitment to the development of the BRAIN AG since 2018 and wish him the most success for his next ventures. We feel very comfortable with the future setup of a two person's board consisting of Adriaan Moelker, CEO, and Lukas Linnig, CFO. Currently we are not planning a succession for Ludger Roedder".
About BRAIN
B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.com.
B.R.A.I.N
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.com
Contact Investor Relations
Michael Schneiders
Head of Investor Relations
Phone: +49-6251-9331-86
E-Mail IR: [email protected]
Media Contact
Dr. Stephanie Konle
Managing Associate
Corporate Communications
Phone +49-6251-9331-70
Email: [email protected]
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)
07.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
B.R.A.I.N. Biotechnology Research And Information Network AG |
|
Darmstädter Straße 34-36 |
|
64673 Zwingenberg |
|
Germany |
Phone: |
+49 (0) 62 51 / 9331-0 |
Fax: |
+49 (0) 62 51 / 9331-11 |
E-mail: |
[email protected] |
Internet: |
www.brain-biotech.com |
ISIN: |
DE0005203947 |
WKN: |
520394 |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
1087561 |
|
End of News |
DGAP News Service |
1087561 07.07.2020
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
24,11 |
27,05 |
38,56 |
38,23 |
38,39 |
45,51 |
55,34 |
EBITDA1,2 |
-7,70 |
-6,55 |
-2,50 |
-3,88 |
-2,53 |
-1,31 |
-0,83 |
EBITDA-Marge3 |
-31,94 |
-24,21 |
-6,48 |
-10,15 |
-6,59 |
-2,88 |
|
EBIT1,4 |
-9,37 |
-9,57 |
-7,20 |
-8,23 |
-6,55 |
-5,65 |
-5,48 |
EBIT-Marge5 |
-38,86 |
-35,38 |
-18,67 |
-21,53 |
-17,06 |
-12,42 |
-9,90 |
Jahresüberschuss1 |
-9,40 |
-8,37 |
-11,12 |
-9,02 |
-4,68 |
-6,34 |
-8,11 |
Netto-Marge6 |
-38,99 |
-30,94 |
-28,84 |
-23,59 |
-12,19 |
-13,93 |
-14,66 |
Cashflow1,7 |
-5,80 |
-5,42 |
-3,38 |
-4,77 |
-3,10 |
-1,49 |
-4,22 |
Ergebnis je Aktie8 |
-0,58 |
-0,45 |
-0,61 |
-0,52 |
-0,25 |
-0,30 |
-0,38 |
Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Baker Tilly
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
BRAIN Biotech |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
520394 |
2,840 |
Halten |
62,05 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
28,40 |
0,00 |
0,00 |
-6,17 |
KBV |
KCV |
KUV |
EV/EBITDA |
2,85 |
- |
1,12 |
-104,88 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
12.03.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
28.02.2024 |
28.05.2024 |
29.08.2024 |
17.01.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-20,98% |
-28,50% |
-22,40% |
-50,52% |
|
|